FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
TheHealthSite7y
Chronic Obstructive Pulmonary Disease
Chronic Pulmonary Obstructive Disease: What are its symptoms and causes and why is it important to quit smoking in the current season. Some people suffer from Asthma and COPD simultaneously ...
Medscape1d
Cilomilast: Orally Active Selective Phosphodiesterase-4 Inhibitor for Treatment of Chronic Obstructive Pulmonary Disease
and airway remodeling associated with chronic obstructive pulmonary disease (COPD). Selective PDE4 inhibition is proposed to maximize the antiinflammatory effects of PDE inhibition while ...
News Medical on MSN18h
New insights into the link between respiratory infections and chronic lung diseases
A 3D reconstruction of a mouse lung four days after infection with fluorescent Sendai virus reveals widespread virus presence (red) and active replication (green).
Rising Kashmir14d
Understanding COPD: A Chronic Lung Disease
Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...
Medscape2d
High Dose N--Acetylcysteine in Patients With Exacerbations of Chronic Obstructive Pulmonary Disease
Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).
Nature2y
Chronic obstructive pulmonary disease articles from across Nature Portfolio
Chronic obstructive pulmonary disease (COPD) is a disease of the respiratory tract that is characterized narrowing of the small airways and destruction of lung tissue. This leads to poor ...
Hosted on MSN24d
Chronic obstructive pulmonary disease (COPD): Signs to watch out for
Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...
Global Chronic Disease Management Market Size to Reach USD 17.28 Billion by 2033 | Witnessing a CAGR of 12.80%
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
framinghamsource2d
New Pulmonary Rehabilitation Program at MetroWest Medical Center is a Breath of Fresh Air for Those with Chronic Lung Disease
For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...
Hosted on MSN9mon
Clearing Up Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease, or COPD, is an umbrella term for lungs with persistent diminished capacity and function caused by other lung-compromising conditions such as emphysema or ...